WIXLIB

Paul GrandAlice Landis-McGrathThomas LipkinCEOExecutive Clinical ConsultantMedTech InnovatorIBM Watson HealthDirector of Entrepreneurship &New VenturesPaul Grand is CEO of MedTechInnovator, the medtech industry’s globalcompetition and accelerator, with amission to improve the lives of patientsby accelerating the development ofstart-ups transforming the health caresystem. He has an extensive globalnetwork in transformative medicalinnovation. Prior to MedTech Innovator,Grand was Managing Director at RCTVentures, an early-stage life scienceinvestor since 2005. At RCT, Grandfocused on medtech investmentsand sourcing innovation. He foundedMedTech Innovator as a program withinRCT Ventures in 2013, and he left torun MedTech Innovator as a standalone company with RCT’s supportin 2016. Prior to RCT, Grand was anentrepreneur, founding and/or servingas CEO in eight companies in lifesciences and technology, includingmost recently Imagine Pharmaceuticals,which developed a platform to delivertherapeutics across the blood brainbarrier and MicroSurgeon, whichdeveloped a thermal ablation devicetreating solid tumors. Grand is activelyinvolved in programs to encouragehealthcare innovation. He has lecturedand mentored students and scientists atnumerous universities, including UCLA,Stanford, USC and UCSF. Grand servedas an investment advisor to the LARTANIH Commercialization AssistanceProgram for SBIR awardees. He is on theOversight Committees for the CoulterTranslational Research PartnershipPrograms at USC and University ofWashington. Grand has reviewed proofof concept and commercializationfocused funding programs for theUniversity of California, USC, Universityof Utah, and University of Colorado.Dr. Alice Landis-McGrath is a memberof IBM Watson Health Oncology andGenomics group, focused on improvingefficiency through the use of cognitivetechnologies at the point of care. Inthis role, Alice provides global clinicalSubject Matter Expert support forWatson for Oncology, Clinical TrialsMatching, and Genomics. Prior tojoining IBM Watson Health, Dr. LandisMcGrath was a Vice President in theConsulting and Management divisionat The Advisory Board Company whereshe led the Optimization service line.She has 17 years of clinical informaticsexperience, including electronicmedical record implementation andoptimization, business process andworkflow redesign, clinical governanceand adoption, reporting and analytics,and IT strategy with a focus on oncologyspecific sales and implementations.During her career, she has workedwith individual ambulatory clinics, smallregional medical centers, large academicinstitutions, and integrated deliverynetworks. Alice received her MD fromthe University of Pennsylvania School ofMedicine, and her BA in Chemistry fromFranklin & Marshall College.4 7TH ANNUAL UCLA MedTech CONFERENCEUCLA Technology DevelopmentGroupThomas Lipkin joined UCLA TDG in 2012and serves as Head of New Ventures.Dr. Lipkin and his team work to furtherthe entrepreneurial environment atUCLA by building start-up companiesaround UCLA’s intellectual property,serving as a resource to facultymembers, aiding existing UCLA start‑upsin sourcing financing and talent, andhelping secure additional fundingfor campus-wide start-up initiatives.Dr. Lipkin is also responsible foractively promoting UCLA’s intellectualproperty assets and engaging withparties interested in further developingearly-stage technologies in the lifesciences, physical sciences, and internettechnology space. Previously, Dr. Lipkinwas with Osage University Partners,a venture capital fund that investsexclusively in university-based start-upcompanies. Dr. Lipkin received his BS inBiology from Indiana University and hisPhD in Cell Biology and Pathology fromColumbia University.

Emily LoughranLuke MacyszynJennifer McCaneySenior Director of Licensing andStrategic AlliancesAssociate Program Director,Department of NeurosurgeryExecutive DirectorUCLA Technology DevelopmentGroupUniversity of California, Los AngelesEmily Loughran joined UCLA TDG in1994 as a technology transfer officer.Currently, as the Senior Director ofLicensing and Strategic Alliancesshe manages the licensing groupin the medical device and physicalsciences space. She oversees theseareas’ large portfolio of inventiondisclosures, patents, and licenseagreements. Additionally Emily haslaunched many strategic initiativesfor TDG; founding and developingbranded and ongoing events such asthe UCLA Annual MedTech PartneringConference, the annual Code for theMission App Competition, Pathways toCommercialization and First Fridays.Emily is also actively involved with theInnovation Fund initiative that TDGmanages. Emily started in intellectualproperty administration at the City ofHope Medical Center where she wasthe Technology Transfer Managerresponsible for patenting and licensingactivities. Emily holds an MBA from USCand a BS from UC Berkeley.Luke Macyszyn is an Assistant Professorof Neurosurgery at UCLA and co-directorof the Neurosurgery Machine LearningLaboratory. He studied biomedicalimage analysis at the University ofPennsylvania, where he developedimage-based clinical decision supporttools using machine learning. Duringhis tenure at Penn he also co-foundedMotionView, a touch-less interface forviewing and manipulating radiologyimages, which took runner up in thePenn iDesign competition. At UCLA, hehas been developing automated tools tohelp physicians diagnose patients withlow back pain using AI. This project hasbeen selected as the winner of the 2017UCLA Innovation Fund competition andis now a funded start-up.UCLA BiodesignJennifer McCaney, PhD, is the ExecutiveDirector of UCLA Biodesign, an earlystage innovation program for healthcaretechnology and Associate Director ofthe UCLA CTSI. Jennifer is an AssistantProfessor in the Department of Medicineat the UCLA David Geffen School ofMedicine and a Lecturer at the AndersonSchool of Management where she leadscourses on disruptive technology andentrepreneurship in healthcare. A cofounder of Hourglass Technologies, aStanford Biodesign company, Jenniferled early product development andalso launched the MedTech InnovatorAccelerator, which grew from an initialcohort of 20 companies to over 150alumni with a combined 700M infunding. Jennifer has worked extensivelywith start-up companies in medtech,digital health and diagnostics, as wellas business development executivesfrom leading manufacturers, includingJ&J, Amgen, Baxter, BD, Olympus,and others in her role as the Directorof MedTech Innovator. A FulbrightScholar, Jennifer completed her PhD inmechanical engineering at Stanford andMS in biomedical engineering from theUniversity of New South Wales. Jenniferholds an MS and BS in mechanicalengineering from MIT where she wasa Draper Fellow and a BS from the MITSloan School of Management.7TH ANNUAL UCLA MedTech CONFERENCE 5

Christos MonovoukasAmir NaibergShyam NatarajanVice President of BusinessDevelopment and StrategyAssociate Vice Chancellor,CEO & PresidentCo-Founder and CEOOlympus Corporation of the AmericasUCLA Technology DevelopmentGroupChristos leads Olympus’ medicalbusiness development and strategyfunction. He analyzes internal andexternal businesses and markets toidentify strategic growth opportunitiesand determine Olympus’ businessstrategy. Christos is a senior executivewith extensive US and internationalsuccess, including evaluating highgrowth market opportunities andemerging technologies, defining strategyand creating roadmaps to achieveobjectives, with particular expertise inthe medical device industry. He drivesimmediate and long-term businessgrowth, plans and executes growthstrategies and creates shareholdervalue. His leadership experience spansall functional areas, including businessdevelopment, market development,strategy, operations, R&D, productdevelopment and manufacturing. He isalso experienced in navigating M&A,funding and venture capital arenas inhighly competitive areas. Christos is adecisive, action-oriented leader whothrives on challenge and is energizedby creating and driving strategy forproduct innovation/commercialization,market development and businessgrowth. He received his MBA fromHarvard University and his MS fromColumbia University.Amir Naiberg serves as AssociateVice Chancellor, and President & CEOof UCLA Technology DevelopmentCorporation. He leads the UCLATechnology Development Group, acampus wide resource that serves as aGateway to Innovation, Research andEntrepreneurship at UCLA. Additionally,he leads the UCLA TechnologyDevelopment Corporation as ChiefExecutive Officer and President, anonprofit technology company whollyowned by UCLA focused on betterprotecting and optimizing the discoveriesand inventions developed throughUCLA research. Mr. Naiberg also worksin concert with several on campusincubators and accelerators to furtheradvance innovation, entrepreneurshipand research at UCLA.6 7TH ANNUAL UCLA MedTech CONFERENCEPrior to joining UCLA in August 2016,Mr. Naiberg worked at Yeda Researchand Development Co, Ltd., in Rehovot,Israel, the technology transfer companyof the Weizmann Institute of Science,ranked as one of the top three technology transfer organizations in the world.At Yeda, he served for ten years as CEO,following five years as General Counsel.He led the organization’s growth in licensing and business partnerships, whilebuilding an entrepreneurial ecosystemwith local incubators, investors, and theIsraeli government. Mr. Naiberg is oneof the founders of the Israel TechnologyTransfer Organization (ITTN), a nonprofitorganization that unites various technology transfer offices throughout Israel.Before joining Yeda, he worked for aprivate law firm specializing in intellectualproperty, privacy and cyberspace law.Mr. Naiberg holds law degrees from theHebrew University School of Law and theUniversity of Connecticut School of Law.Avenda HealthShyam Natarajan is Co-founder andCEO of Avenda Health, a clinicalstage healthcare technology companyfocused on personalized prostatecancer treatment. He is also anAssistant Adjunct Professor in theUCLA Departments of Urology andBioengineering. Prior to Avenda, he ledresearch efforts in developing imageguided interventions for prostate cancerat the Center for Advanced Surgicaland Interventional Technology (CASIT)and has authored more than 50 peerreviewed publications. His work wasinstrumental in the clinical translation andcommercialization of targeted prostatebiopsy. Dr. Natarajan additionally servedas a Program Manager in the Businessof Science Center, launching campusinitiatives in entrepreneurship suchas Innovation Week and Inventathon,Southern California’s first healthcarehackathon. He received a BS inComputer Engineering and BA inJapanese from UC Santa Barbara,and a PhD in Biomedical Engineeringfrom UCLA, where he also completedpostdoctoral work within the Departmentof Surgery.

Jonathan NorrisJenell Paul-RobinsonKelly Larrabee RobkeManaging Director,Healthcare PracticeVice President, Clinical Value andProvider RelationsVice President, Clinical ThoughtLeadershipSilicon Valley BankMedTech InnovatorBD Medical AffairsJonathan Norris is a Managing Directorof Venture Capital Relationships forSilicon Valley Bank. Norris overseesbusiness development efforts forbanking and lending opportunitiesas well as spearheading strategicrelationships with many life scienceand healthcare venture capital firms.He also helps SVB Capital throughsourcing and advising on limitedpartnership allocations. In addition, hespeaks at major investor and industryconferences and authors widely citedanalyses of healthcare venture capitaltrends. Norris has more than sixteenyears of banking experience workingwith healthcare companies and venturecapital firms. Norris earned a bachelor’sdegree in business administration fromthe University of California, Riversideand a juris doctorate from Santa ClaraUniversity.Jenell Robinson, MSN, RN is VicePresident, Clinical Value and ProviderRelations at MedTech Innovator.MedTech Innovator is the industry’snonprofit global competition andaccelerator for medical device, digitalhealth and diagnostic companies.She brings over 20 years of clinical,operational, and administrativehealthcare expertise to the MedTechInnovator team. Jenell providesinsight and expertise to innovativestart‑ups on value propositions,clinical potential and feasibility. Earlyin her nursing career, Jenell becamea travel nurse, gaining experience inmultiple care settings, ranging fromsmall, private community hospitals,to large, metropolitan academicmedical centers. Through her travels,she became particularly interestedin heart and lung transplantation,specializing in cardiothoracic intensivecare for both the pediatric and adultpatient population. After joininghospital operations management,Jenell received her master’s degreein Nursing Administration from UCLA.She served on several nationalsupply chain and academic medicalcenter value analysis professionalcommittees, offering expertise in valueanalysis and assessment for hospitalpurchasing decisions. She is the authorof “Technology Adoption: Appealingto hospital and health system valueanalysis” in Medical Innovation: Conceptto Commercialization.Kelly is currently the Vice Presidentof Clinical Thought Leadership for theMedication Management Solutionsorganization of BD. She is responsiblefor engaging leaders in clinicalpractice, associations, and healthcareorganizations in driving knowledgeof clinical issues as well as extendingeducational and publication initiativesfor the business. She previously workedin leadership roles for the Pyxis ProductManagement group at BD, leadingefforts to launch Pyxis EnterpriseSystem and Medlink. Prior to her tenureat BD, Kelly successfully developed,led and grew cross functional teamsresponsible for the delivery of healthcareinnovation and technology in positionsat the M.D. Anderson Cancer Center,Pfizer Oncology, Hewlett Packard, andOracle. As a Registered Nurse, Kellyhas been responsible for direct patientcare of high risk obstetrical patients,and also worked as an oncology nurse.She has published original researcharticles in Obstetrics and Gynecology,American Journal of Obstetrics andGynecology, the Journal of Perinataland Neonatal Nursing, and the Monitor.Kelly received her Bachelor of Sciencedegree in Nursing from West VirginiaUniversity, an MBA from the Universityof Houston, and a Master’s of Science inRegulatory Affairs from the University ofSouthern California.7TH ANNUAL UCLA MedTech CONFERENCE 7

Murray SheldonAnne E. SisselMaie A. St. JohnAssociate Director of Technologyand Innovation Center forDevices and Radiologic HealthVice President, Baxter VenturesProfessor and Chair, Departmentof Head & Neck SurgeryBaxter Healthcare CorporationFDADr. Murray Sheldon, MD received hismedical degree from the Universityof Michigan Medical School in 1975and his cardiovascular fellowship atthe Montefiore Hospital and MedicalCenter in New York. After practicingcardiac, thoracic and vascular surgeryin Northern California for over 20 years,he entered the medical device industry,leading device development projectsand providing expert consultativeservices to numerous start-upinnovative medical device developmentfirms. Dr. Sheldon joined the FDA in2013 as the Associate Director forTechnology and Innovation overseeingthe Center’s initiative to proactivelyfacilitate medical device innovation toaddress unmet public health needsand to align what is traditionally doneat FDA with what is required to supportthe US medical device ecosystem.His primary focus is working with FDAstaff, the medical device industry,the clinical community and otherstakeholders on ways to facilitatebringing innovative medical devicesto the patients in the US first in theworld. Dr. Sheldon currently leads theMedical Device Payer CommunicationTask Force, identifying methods tostreamline the path from FDA approvalto reimbursement.8 7TH ANNUAL UCLA MedTech CONFERENCEAnne Sissel is the Vice President andHead of Baxter Ventures. Previous toBaxter, Anne was on the founding teamand executive team for Veracyte, Inc.(now NASDAQ: VCYT). Anne led thefinance and business developmentorganization and was a cross-functionalleader from early discovery throughcommercialization. Prior to Veracyte,Anne worked in the InvestmentBanking Division of Goldman, Sachs& Co. in New York and San Francisco,completing over 200bn in financingand M&A transactions. Anne holdsan MBA from the Wharton School ofthe University of Pennsylvania and aBS in Finance from Indiana University.She was selected to Crain’s ChicagoBusiness Top 40 Under 40 in 2016 andtheir Top 50 in Tech in 2015. Anne’scurrent Board and Observation rolesrepresenting Baxter include: Kit Check,Medasense, Prescient Surgical, Sanifitand VitalConnect.David Geffen School of Medicineat UCLAA highly renowned surgeon, scientistand educator, Dr. St. John is Professorand Chair of Department of Head andNeck Surgery at the David GeffenSchool of Medicine at UCLA. She alsoholds the Samuel and Della PearlmanChair in Head and Neck Surgery andis Co-Director of the UCLA Head andNeck Cancer Program. Dr. St. John’slaboratory studies the mechanisms oftumor progression and metastasis inhead and neck cancer and seeks toidentify and study novel genes andpathways for future targeted therapies,while actively incorporating the resultsof their laboratory-based research intothe development of novel therapeutics.Dr. St. John received her undergraduatedegree from Stanford University andboth MD and PhD degrees from YaleUniversity. She completed residencyand postdoctoral training at UCLA andserved previously as Chief of Headand Neck Surgery at Harbor-UCLAMedical Center. Dr. St. John’s clinicalexpertise is in intraoperative tumormargin delineation in the resection andtreatment of head and neck cancers.Her laboratory research is translationalwith a focus on improving therapies andoutcomes for patients with head andneck cancer.

George TolomiczenkoKwame UlmerJimmy WhitesidesAdvisory Board Member for TheCenter for Technology and Innovationin Pediatrics (CTIP)Venture PartnerUS Marketing Director,Critical CareWavemaker Three-Sixty HealthCo-Director for The USC CoulterEdwards LifesciencesAdministrative Director for HTE@USCExpert in fund development andmanagement including negotiations,contracting, policy formulation, and otheractivities related to fundraising fromcorporations, partner funders, volunteersand high net-worth individuals.Demonstrated success in negotiatingwin-win agreements in multi-sectororganizational and research partnershipswith federal, provincial, academic andhealth charity stakeholders acrossCanada and the US. Leadership andresearch responsibilities for complexhealthcare projects and externalpartnerships related to developing largeand small-scale project managementand data collection efforts for programdevelopment and marketing.Kwame Ulmer is a venture partner atWavemaker Three-Sixty Health—theleading Southern-California based, earlystage venture capital firm (Seed andSeries A) focused on the healthcareindustry. He participates in all aspects offund management (e.g. deal sourcing,diligence, negotiation and advisingportfolio company managementteams). Kwame brings nearly 20 yearsof experience evaluating medicaltechnologies in the government andprivate sector, and serving in senioroperating roles at medical devicecompanies. He has personally evaluatedmore than 1,000 medical technologiesin his career. Kwame spent 12 years atthe US Food and Drug Administration(FDA) in progressive leadership roles,including Deputy Director and BranchChief. He also served as Vice President,Regulatory Affairs and Quality Assuranceat Implant Direct, a Danaher Corporationoperating company. He is a member ofthe Executive Committee of Tech CoastAngels (LA), the world’s largest angelinvesting network. Kwame earned his BSin Physics from Lincoln University, andhas two Master’s degrees from Universityof Virginia, in Materials Engineering andBusiness Administration.Jimmy Whitesides has been withEdwards Lifesciences since Marchof 2009 and is currently responsiblefor the company’s US Critical Caremarketing organization. Jimmy hasheld a variety of roles with increasinglevels of responsibility. He was the leadmarketer following the acquisition ofthe noninvasive ClearSight technologyand led subsequent launches inEurope, the US and Japan. Jimmyalso served as the heavy weightteam lead for Edwards’ closed loopdevelopment initiatives. He graduatedfrom Brigham Young University andearned his master’s degree in businessadministration from the University ofSouthern California.7TH ANNUAL UCLA MedTech CONFERENCE 9

Erich WohlhieterKathryn ZavalaExecutive Director, Digital Health& InnovationVice President, Operations &Business DevelopmentAmgenMedTech InnovatorErich Wohlhieter has been at Amgenover 16 years in a variety of rolesspanning research, corporatetransformation and strategy, and iscurrently an Executive Director inAmgen’s Digital Health and Innovationgroup. Erich received his Bachelor’sin Chemistry from the University ofCalifornia, Berkeley and his PhD inOrganic Chemistry from the Universityof California, Los Angeles.Kathryn Zavala is the Vice President,Operations & Business Development atMedTech Innovator, a nonprofit globalcompetition and accelerator for medicaldevice, digital health, and diagnosticcompanies. She previously held aposition as Senior Technology Fellowat the UCLA Technology DevelopmentGroup, where she assisted withthe commercializ

innovation. Prior to MedTech Innovator, Grand was Managing Director at RCT Ventures, an early-stage life science investor since 2005. At RCT, Grand focused on medtech investments and sourcing innovation. He founded MedTech Innovator as a program within RCT Ventures in 2013, and he left to run MedTech Innovator as a stand-